Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 17/20 | 0.56 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | GNA15 | P30679 | 1/20 | 0.35 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.35 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.35 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.35 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.35 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23952772 | 1.00 | FFAR1 (0.56) | FFAR1FFAR4CD274DGAT1GNA15 | |
| SCHEMBL19670781 | 1.00 | FFAR1 (0.56) | FFAR1FFAR4CD274DGAT1GNA15 | |
| SCHEMBL18963536 | 1.00 | FFAR1 (0.56) | FFAR1FFAR4CD274DGAT1GNA15 | |
| SCHEMBL15471467 | 0.93 | FFAR1 (0.62) | FFAR1FFAR4DGAT1CYP2C8CYP2C9 | |
| SCHEMBL15464467 | 0.93 | FFAR1 (0.62) | FFAR1FFAR4DGAT1CYP2C8CYP2C9 | |
| SCHEMBL16846007 | 0.91 | FFAR1 (0.51) | FFAR1FFAR4CD274 | |
| SCHEMBL16829648 | 0.91 | FFAR1 (0.51) | FFAR1FFAR4CD274 | |
| SCHEMBL29423892 | 0.91 | FFAR1 (0.51) | FFAR1FFAR4CD274 | |
| SCHEMBL16855673 | 0.91 | FFAR1 (0.51) | FFAR1FFAR4CD274 | |
| SCHEMBL18959427 | 0.89 | FFAR1 (0.43) | FFAR1FFAR4CD274DGAT1GNA15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3974413-A1 | ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2022-03-30 | — | — | EP | disclosed |
| EP-3082786-B1 | ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS | MERCK SHARP & DOHME (US) | 2021-10-27 | — | — | EP | disclosed |
| US-9834563-B2 | Antidiabetic substituted heteroaryl compounds | MERCK SHARP & DOHME CORP. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834563-B2 | Antidiabetic substituted heteroaryl compounds | MERCK SHARP & DOHME CORP. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834563-B2 | Antidiabetic substituted heteroaryl compounds | MERCK SHARP & DOHME CORP. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170166578-A1 | ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS | MERCK SHARP & DOHME LLC | 2017-06-15 | — | — | US | disclosed |
| US-20170166578-A1 | ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS | MERCK SHARP & DOHME LLC | 2017-06-15 | — | — | US | disclosed |
| US-20170166578-A1 | ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS | MERCK SHARP & DOHME LLC | 2017-06-15 | — | — | US | disclosed |
| WO-2015095256-A1 | ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015089809-A1 | ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166578-A1 | ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS | GPR119, GPR65, GPR55 | FFAR1 13/4885FFAR4 10/4885CD274 4582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.